[{"id":"b6df07b6-a88e-4791-862f-2c9826b94a75","acronym":"LIFT","url":"https://clinicaltrials.gov/study/NCT01275209","created_at":"2021-02-26T05:52:10.861Z","updated_at":"2024-07-02T16:36:37.648Z","phase":"Phase 1","brief_title":"Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma","source_id_and_acronym":"NCT01275209 - LIFT","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD40","pipe":"","alterations":" ","tags":["CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • LymphoCide Y-90 (epratuzumab Y-90) • lucatumumab (CHIR 12.12)"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 02/01/2011","start_date":" 02/01/2011","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 05/01/2012","study_completion_date":" 05/01/2012","last_update_posted":"2020-12-08"}]